At a glance
- Originator Kyoto Pharmaceutical Industries
- Class Antiplatelets; Imidazoles; Small molecules; Thrombolytics
- Mechanism of Action Free radical scavengers; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Myocardial ischaemia
Most Recent Events
- 06 Mar 2008 Discontinued - Preclinical for Asthma in Japan (unspecified route)
- 06 Mar 2008 Discontinued - Preclinical for Myocardial ischaemia in Japan (unspecified route)
- 06 Jun 2001 No-Development-Reported for Asthma in Japan (Unknown route)